Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: Amir T. Fathi (15313195) (author)
Awduron Eraill: Haesook T. Kim (15313198) (author), Robert J. Soiffer (15313201) (author), Mark J. Levis (15313204) (author), Shuli Li (15313207) (author), Annette S. Kim (15117505) (author), Zachariah DeFilipp (15313210) (author), Areej El-Jawahri (15313213) (author), Steve L. McAfee (15313216) (author), Andrew M. Brunner (15313219) (author), Philip C. Amrein (15313222) (author), Alice S. Mims (11016414) (author), Laura W. Knight (15313225) (author), Devon Kelley (15313228) (author), AJ S. Bottoms (15313231) (author), Lindsey H. Perry (15313234) (author), Jonathan L. Wahl (15313237) (author), Jennifer Brock (15313240) (author), Elayne Breton (15313243) (author), Dylan M. Marchione (14935655) (author), Vincent T. Ho (15313246) (author), Yi-Bin Chen (15313249) (author)
Cyhoeddwyd: 2025
Pynciau:
Cancer
Therapeutic Research and Development
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Oncoprotein & tumor suppressor drug targets
Hematological Cancers
Leukemias
Immunotherapy
Stem cell transplantation
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
Disgrifiad
Crynodeb:<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>

Eitemau Tebyg